VivoSeq
Oncology

Angioimmunoblastic T-Cell Lymphoma

20

Pipeline Programs↗

0

Active Trials↗

13

Companies Involved↗

Angioimmunoblastic T-Cell Lymphoma is an emerging landscape with 20 programs across 13 companies. The most active players are Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Bristol-Myers Squibb, Innovent Biologics (Suzhou) Co. Ltd.. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

40/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

3 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2C

Chipscreen Biosciences, Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

17 of 18 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody16%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 95% of 20 pipeline programs.

Analysis

Trial Status

7

clinical trials

Completed2 · 29%
Unknown status2 · 29%
Terminated2 · 29%
Suspended1 · 14%

Clinical Trials

Trial Activity

7 trials

Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT01553786·80 enrolled
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT02273739·21 enrolled
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
Suspended·Alliance for Clinical Trials in Oncology·Phase 2·NCT04803201·170 enrolled
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Terminated·PPharmaMar·Phase 2·NCT03070964·14 enrolled
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
Terminated·EEastern Cooperative Oncology Group·Phase 2·NCT00070291·4 enrolled
Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
Unknown status·CCancer Research UK·Phase 2·NCT00958854·37 enrolled
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT05179213·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)